接受长期长效注射抗逆转录病毒治疗HIV感染者的利匹韦林与卡博特韦谷浓度
该研究纳入67例接受长效注射抗逆转录病毒治疗至少32周的HIV感染者,评估利匹韦林与卡博特韦血浆谷浓度分布。卡博特韦个体间变异(45%)低于利匹韦林(84%)(P<0.05);67例中3例至少一次药物浓度低于4×PA-IC90,但100%感染者HIV病毒载量检测不到。
要点
- 长期长效注射治疗下,卡博特韦谷浓度个体间变异45%,低于利匹韦林的84%(P<0.05)。
- 67例中3例至少一次药物浓度低于4×PA-IC90,全部感染者HIV病毒载量检测不到。
- 男女性别间利匹韦林与卡博特韦谷浓度无显著差异,BMI>30 kg/m2者卡博特韦浓度呈非显著降低趋势。
核心结论
- 在稳态下,大多数HIV感染者卡博特韦和利匹韦林全身暴露 optimal;卡博特韦谷浓度个体间变异低于利匹韦林。
- 研究因女性和肥胖感染者人数少,不足以评估性别和/或体重对长效注射暴露的贡献。
研究设计与样本
- 研究纳入67例接受长效注射抗逆转录病毒治疗至少32周并评估药物血浆谷浓度的成年HIV感染者。
- 长效注射治疗持续时间为216 ± 80周(范围32-320周)。
主要发现
- 卡博特韦浓度个体间变异为45%,利匹韦林为84%(P<0.05)。
- 男性(n=55)与女性(n=12)利匹韦林谷浓度分别为160 ± 118与189 ± 81 ng/mL(P=0.430),卡博特韦分别为1758 ± 807与1969 ± 802 ng/mL(P=0.416)。
- 体重指数>30 kg/m2者(n=9)与非肥胖者卡博特韦谷浓度分别为1916 ± 905与1606 ± 576 ng/mL(P=0.131)。
- 67例中3例至少一次药物浓度低于4×PA-IC90,100%感染者HIV病毒载量检测不到。
关键数值与推荐
- 低于4倍抑制病毒复制所需蛋白调整浓度的比例:67例中3例至少一次药物浓度低于4×PA-IC90。
- 利匹韦林与卡博特韦谷浓度个体间变异:卡博特韦45% vs 利匹韦林84%(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究因纳入女性和肥胖HIV感染者人数少,不足以评估性别和/或体重对长效注射暴露的贡献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Large inter-individual variability in the pharmacokinetics of rilpivirine and cabotegravir has been reported in the first weeks after starting long-acting injectable (LAI) therapy. Here, we assessed the distribution of rilpivirine and cabotegravir trough concentrations in people with HIV (PWH) on long-term LAI treatment. METHODS: Adult PWH treated with LAI for at least 32 weeks with an assessment of drug plasma trough concentrations were considered. The proportion of rilpivirine and cabotegravir plasma trough concentrations below four-times the protein-adjusted concentrations required for 90% inhibition of viral replication (4×PA-IC90) was estimated. RESULTS: Sixty-seven PWH were identified. LAI treatment duration was 216 ± 80 weeks (range 32-320 weeks). Cabotegravir concentrations were associated with lower inter-individual variability compared with rilpivirine (45% versus 84%; P < 0.05). No differences were found in rilpivirine (160 ± 118 versus 189 ± 81 ng/mL; P = 0.430) and cabotegravir (1758 ± 807 versus 1969 ± 802 ng/mL; P = 0.416) trough concentrations in males (n = 55) versus females (n = 12). A non-significant trend for lower cabotegravir concentrations was found in PWH with a body mass index >30 kg/m2 (n = 9) versus non-obese participants (1916 ± 905 versus 1606 ± 576 ng/mL; P = 0.131). Three out of the 67 PWH had at least one drug concentration <4×PA-IC90: 100% of PWH had undetectable HIV viral load. CONCLUSIONS: At steady state, optimal systemic exposure of cabotegravir and rilpivirine was found in most PWH; cabotegravir trough concentrations were associated with lower inter-individual variability compared with rilpivirine. The study was not powered to assess the contribution of sex and/or body weight on LAI exposure due to the small number of females and obese PWH included.
引用
- Cossu MV, Cattaneo D, Moschese D, et al. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals. J Antimicrob Chemother. 2024. PMID: 38530862. doi:10.1093/jac/dkae080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。